New targeted drug trial offers hope for tough pancreatic cancer
NCT ID NCT07450859
Summary
This study is testing an experimental drug called BT5528 for adults with advanced pancreatic cancer that has spread and worsened after one prior treatment. The drug is designed to find and attack cancer cells by targeting a specific protein they often have. Researchers want to see if the drug shrinks tumors, how safe it is, and how the body processes it. All 39 participants will receive the drug, and both they and their doctors will know what treatment is being given.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Thomas Jefferson University, Sidney Kimmel Comprensive Cancer Center, Clinical Trials Office
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.